Next Article in Journal
Validation of a Novel Zebrafish Model of Dengue Virus (DENV-3) Pathology Using the Pentaherbal Medicine Denguenil Vati
Previous Article in Journal
TOP mRNPs: Molecular Mechanisms and Principles of Regulation
Previous Article in Special Issue
Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists
Open AccessArticle

Development and Characterization of a Fucoidan-Based Drug Delivery System by Using Hydrophilic Anticancer Polysaccharides to Simultaneously Deliver Hydrophobic Anticancer Drugs

1
Department of Materials Science and Engineering, National Chiao Tung University, Hsinchu 30010, Taiwan
2
Cell Therapy Center, China Medical University Hospital, Taichung 40454, Taiwan
3
Frontier Research Centre on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan
4
School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung ‎80708, Taiwan
5
Graduate Institute of Biomedical Science, China Medical University, Taichung 40454, Taiwan
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(7), 970; https://doi.org/10.3390/biom10070970
Received: 4 June 2020 / Revised: 25 June 2020 / Accepted: 26 June 2020 / Published: 28 June 2020
Fucoidan, a natural sulfated polysaccharide, which can activate the immune response and lessen adverse effects, is expected to be an adjuvant agent in combination with chemotherapy. Using natural hydrophilic anticancer polysaccharides to simultaneously encapsulate hydrophobic anticancer drugs is feasible, and a reduced side effect can be achieved to amplify the therapeutic efficacy. In this study, a novel type of fucoidan-PLGA nanocarrier (FPN-DTX) was developed for the encapsulation of the hydrophobic anticancer drug, docetaxel (DTX), as a drug delivery system. From the comparison between FPN-DTX and the PLGA particles without fucoidan (PLGA-DTX), FPNs–DTX with fucoidan were highly stable with smaller sizes and dispersed well without aggregations in an aqueous environment. The drug loading and release can be further modified by modulating relative ratios of Fucoidan (Fu) to PLGA. The (FPN 3-DTX) nanoparticles with a 10:3 ratio of Fu:PLGA displayed uniform particle size with higher encapsulation efficiency than PLGA NPs and sustained drug release ability. The biocompatible fucoidan-PLGA nanoparticles displayed low cytotoxicity without drug loading after incubation with MDA-MB-231 triple-negative breast cancer cells. Despite lower cellular uptake than that of PLGA-DTX due to a higher degree of negative zeta potential and hydrophilicity, FPN 3-DTX effectively exerted better anticancer ability, so FPN 3-DTX can serve as a competent drug delivery system. View Full-Text
Keywords: fucoidan; PLGA; docetaxel; drug delivery system; anticancer therapy/cancer treatment fucoidan; PLGA; docetaxel; drug delivery system; anticancer therapy/cancer treatment
Show Figures

Figure 1

MDPI and ACS Style

Lai, Y.-H.; Chiang, C.-S.; Hsu, C.-H.; Cheng, H.-W.; Chen, S.-Y. Development and Characterization of a Fucoidan-Based Drug Delivery System by Using Hydrophilic Anticancer Polysaccharides to Simultaneously Deliver Hydrophobic Anticancer Drugs. Biomolecules 2020, 10, 970.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop